All revved up and ready to roll, Roche is hand­ed the keys to a multi­bil­lion-dol­lar he­mo­phil­ia mar­ket

Roche has a green light to great­ly ex­pand its sales ef­fort be­hind Hem­li­bra, the land­mark he­mo­phil­ia drug that is mak­ing mar­ket­ing life mis­er­able at Shire.

The FDA has rolled out an ap­proval for the glob­al heavy­weight to start sell­ing their drug — a break­through that has nev­er­the­less stirred some un­easi­ness on the safe­ty side — to pa­tients who have yet to de­vel­op fac­tor VI­II in­hibitors. That mar­ket is sev­er­al times larg­er than the ini­tial group Roche gained ac­cess to last year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER